Pfizer scored new Crohn’s data that could give its Remicade biosimilar, Inflectra, more oomph for its market-share fight, one of the first U.S. head-to-heads…

AbbVie’s former blockbuster AndroGel faces a class-action lawsuit over side effects—and a trial of a different sort as new testosterone-replacement data paint…

Ahead of the Supreme Court’s hearing in Amgen v. Sandoz “patent dance” case, biosimilars advocates are criticizing a lower court's 'detrimental…

Celgene’s late-stage pill, ozanimod, could hit $2b in sales and add pressure to an already competitive oral MS market, analysts say.

AstraZeneca snagged $250 million-plus for its cancer drug Zoladex in the U.S., where it brought in only $69 million last year. The deal, AZ's latest slim-…

Stada said it has a third suitor in the mix to buy the company, and Bernstein analyst Ronny Gal thinks he may know who it is.

The impending approval of Momenta's copy of Teva’s long-acting version of blockbuster Copaxone is now expected to be delayed.

Roche’s Genentech has sued Amgen for not giving up the info Genentech experts need to mount a patent infringement attack on Amgen’s biosimilar for Avastin, its…

Friday, AZ showed that it's PARP inhibitor Lynparza, currently approved in ovarian cancer, is more than a one-trick pony.

Pharma